Herpes zoster: Daily marking of new vesicles in therapeutic studies: A clinical method for objective assessment of the end of the eruptive phase
- 31 December 1993
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 29 (6) , 970-973
- https://doi.org/10.1016/0190-9622(93)70276-y
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- 2'-Fluoro-5-Iodoarabinosylcytosine, a New Potent Antiviral Agent: Efficacy in Immunosuppressed Individuals with Herpes ZosterThe Journal of Infectious Diseases, 1986
- Treatment of Varicella–Zoster Virus Infection in Severely Immunocompromised PatientsNew England Journal of Medicine, 1986
- ACYCLOVIR TREATMENT OF VARICELLA-ZOSTER VIRUS INFECTION IN THE COMPROMISED HOST1Transplantation, 1984
- Acyclovir Halts Progression of Herpes Zoster in Immunocompromised PatientsNew England Journal of Medicine, 1983
- Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed PatientsNew England Journal of Medicine, 1982
- ACYCLOVIR THERAPY FOR ACUTE HERPES ZOSTERThe Lancet, 1982
- ACYCLOVIR IN HERPES ZOSTERThe Lancet, 1981
- Prolonged Herpes-Zoster Infection Associated with Immunosuppressive TherapyAnnals of Internal Medicine, 1979